Tracking cancer drug performance in everyday patients
NCT ID NCT04945330
Summary
This study collects real-world information about larotrectinib, an existing cancer drug for TRK fusion cancer. Researchers will follow 100 patients (adults and children) whose cancer has spread or returned, tracking side effects and treatment effectiveness during normal doctor visits. The goal is to better understand how this drug works in everyday medical practice rather than in controlled clinical trials.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED OR RECURRENT SOLID TUMOR HARBORING AN NTRK GENE FUSION are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Many locations
RECRUITINGMultiple Locations, Japan
Conditions
Explore the condition pages connected to this study.